Development of radiolabeled humanized monoclonal antibodies for therapy using gene technology.

点击翻译按钮获取中文摘要

This research project was performed to investigate the radiolabeled humanized monoclonal antibodies developed by gene technology.Monoclonal antibodies are expected to bind to the tumor expressing the corresponding antigens. For this purpose murine monoclonal antibodies are used for the diagnostic imagings and the therapy of cancers. However, antibodies derived from mice may cause allergic reactions, when administered to patients, due to the species difference. In order to decrease the immunogenecity of murine monoclonal antibodies, humanized antibodies are produced by using the gene technology. In the present study, ィイD1131ィエD1I-labeled murine monoclonal antibodies reactive with CD20 B cell antigen were investigated in the animals and confirmed to accumulate in the transplanted tumor. After getting the permission from the ethical committee of our institute ィイD1131ィエD1I-labeled antibody against CD20 antigen was safely administered to patients with non-Hodgkin lymphoma. Further studies remains to be in vestigated.ィイD1131ィエD1I-labeled monoclonal antibody named A33 was humanized and administered to gastric cancer patients (Co-investigator Junichi Sakamoto, M.D. of Aichi Prefectural Hospital and Hiroyuki Kuwano, M.D. of Gunma University Hospital). This antibody accumulated to cancer tissue with tumor to blood ratios of about 2 and tumor to normal tissue ratio of about 4.For the therapy of various diseases, new radionuclides have been investigated such as rhenium-186 and yttrium-90, which are expected to have favorable characteristics for clinical use.